HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models. However, its activity in other type of cancers has not yet been shown. In this study, we further evaluated the biologic sequelae of WT161 in breast cancer cell lines. WT161 triggers apoptotic cell death in MCF7, T47D, BT474, and MDA-MB231 cells, associated with decreased expression of EGFR, HER2, and ERα and downstream signaling. However, HDAC6 knockdown shows that cytotoxicity and destabilization of these receptors triggered by WT161 are not dependent on HDAC6 inhibition. Moreover WT161 analog MAZ1793, which lacks HDAC inhibitory effect, similarly triggers cell line growth inhibition and downregulation of these receptors. We also confirm that WT161 significantly inhibits in vivo MCF7 cell growth, associated with downregulation of ERα, in a murine xenograft model. Finally, WT161 synergistically enhances bortezomib-induced cytotoxicity, even in bortezomib-resistant breast cancer cells. Our results therefore provide the rationale to develop a novel class of therapeutic agents targeting growth pathways central to the pathogenesis of breast cancer.

[1]  S. Jagannath,et al.  Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma , 2017, Clinical Cancer Research.

[2]  J. Harrell,et al.  HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth. , 2017, Molecular cancer research : MCR.

[3]  P. Richardson,et al.  Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. , 2016, The Lancet. Oncology.

[4]  S. Schreiber,et al.  Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma , 2016, Proceedings of the National Academy of Sciences.

[5]  J. Harrell,et al.  HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth , 2016, Molecular Cancer Research.

[6]  Miao-Hsia Lin,et al.  The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42 , 2016, Nature Communications.

[7]  J. Bradner,et al.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. , 2012, Blood.

[8]  L. Rimsza,et al.  A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517 , 2012, Leukemia & lymphoma.

[9]  N. Munshi,et al.  Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. , 2011, Blood.

[10]  F. Waharte,et al.  HDAC6 is required for invadopodia activity and invasion by breast tumor cells. , 2011, European journal of cell biology.

[11]  M. Dimopoulos,et al.  Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. , 2010, Leukemia research.

[12]  J. Friedberg,et al.  The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. , 2010, Blood.

[13]  Tatsushi Yoshida,et al.  Blockade of Rac1 Activity Induces G1 Cell Cycle Arrest or Apoptosis in Breast Cancer Cells through Downregulation of Cyclin D1, Survivin, and X-Linked Inhibitor of Apoptosis Protein , 2010, Molecular Cancer Therapeutics.

[14]  D. Carrasco,et al.  A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. , 2010, Blood.

[15]  E. Levin,et al.  Heat Shock Protein 27 Is Required for Sex Steroid Receptor Trafficking to and Functioning at the Plasma Membrane , 2010, Molecular and Cellular Biology.

[16]  Xiong Cai,et al.  CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. , 2010, Cancer research.

[17]  T. Yao,et al.  The Microtubule-associated Histone Deacetylase 6 (HDAC6) Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation* , 2010, The Journal of Biological Chemistry.

[18]  Adrian V. Lee,et al.  Proteasome inhibition represses ERα gene expression in ER+ cells- a new link between proteasome activity and estrogen signaling in breast cancer , 2009, Oncogene.

[19]  M. Maitland,et al.  Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Protopopov,et al.  Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. , 2009, Blood.

[21]  K. Horie-Inoue,et al.  Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. , 2009, Cancer research.

[22]  Seung-Woo Hong,et al.  p34SEI-1 inhibits apoptosis through the stabilization of the X-linked inhibitor of apoptosis protein: p34SEI-1 as a novel target for anti-breast cancer strategies. , 2009, Cancer research.

[23]  Kwun Chuen Gary Chan,et al.  Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment , 2009, Clinical Cancer Research.

[24]  L. Altucci,et al.  Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells , 2008, Molecular Cancer Research.

[25]  S. Horinouchi,et al.  Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. , 2008, Biochemical and biophysical research communications.

[26]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[27]  Gordon K Smyth,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[28]  F. Sánchez‐Madrid,et al.  HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. , 2008, Trends in cell biology.

[29]  Wei Wei,et al.  Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. , 2008, Biochemical pharmacology.

[30]  M. Munsell,et al.  NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. , 2007, Blood.

[31]  M. Krönke,et al.  NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. , 2007, Blood.

[32]  N. Rosen,et al.  An acetylation site in the middle domain of Hsp90 regulates chaperone function. , 2007, Molecular cell.

[33]  K. Anderson,et al.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. , 2006, Blood.

[34]  Yu-Ying He,et al.  Cleavage of epidermal growth factor receptor by caspase during apoptosis is independent of its internalization , 2006, Oncogene.

[35]  K. Anderson,et al.  Intracellular Protein Degradation and Its Therapeutic Implications , 2005, Clinical Cancer Research.

[36]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[37]  S. Schreiber,et al.  Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer , 2005, Oncogene.

[38]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[39]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[41]  E. Bennett,et al.  Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. , 2005, Molecular cell.

[42]  Simak Ali,et al.  Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines , 2004, Clinical Cancer Research.

[43]  Hiroko Yamashita,et al.  HDAC6 Expression Is Correlated with Better Survival in Breast Cancer , 2004, Clinical Cancer Research.

[44]  M. Vasconcelos,et al.  Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells , 2004, Cancer Gene Therapy.

[45]  S. Hilsenbeck,et al.  Hsp27 overexpression inhibits doxorubicin–induced apoptosis in human breast cancer cells , 1999, Breast Cancer Research and Treatment.

[46]  Simak Ali,et al.  Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[48]  D. Chauhan,et al.  Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. , 2003, Cancer research.

[49]  S. Zhuang,et al.  Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases , 2003, Oncogene.

[50]  N. Munshi,et al.  Molecular sequelae of histone deacetylase inhibition in human malignant B cells. , 2003, Blood.

[51]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[53]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[54]  S. Srinivasula,et al.  Structural Basis of Caspase-7 Inhibition by XIAP , 2001, Cell.

[55]  Christian Stehlik,et al.  Nuclear Factor (NF)-κB–regulated X-chromosome–linked iap Gene Expression Protects Endothelial Cells from Tumor Necrosis Factor α–induced Apoptosis , 1998, The Journal of experimental medicine.